Intra-Cellular Therapies Inc. (Nasdaq: ITCI) reported disappointing results from a Phase 3 trial of ITI-007 to treat schizophrenia prompting a downgrade. Shares of the biopharmaceutical plummeted $26.93 to close at $15.42.
Disappointing study results for Intra-Cellular Therapies
September 29, 2016 at 18:46 PM EDT
